‘Gamechanger’ HIV prevention drug to be made available cheaply in 120 countries
by Kat Lay, Global health correspondent from Science | The Guardian on (#6R6RC)
Gilead Sciences announces deal to manufacture generic versions of lenacapavir, but critics say it excludes many countries where incidence is highest
Cheaper versions of the gamechanger" HIV prevention drug lenacapavir are to be made available in 120 low- and middle-income countries, manufacturer Gilead Sciences has announced.
However, campaigners said the deal abandons" many countries with a high HIV burden, particularly in Latin America, and urged transparency over exact pricing.
Continue reading...